Insulin formulation

Details Insulin formulation Insulin formulation

1993-08-13

1996-07-09

Warden, Jill

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 4, 530303, 530304, A61K 3828

Patent

active

055344887

ABSTRACT:
The present invention is directed to an insulin formulation comprising a suspension of Ultralente crystals and a total formulation zinc concentration of between about 0.5 milligrams to about 20 milligrams per 100 units of insulin. Greater than fifty percent of the total zinc in the formulation resides in the soluble fraction, rather than in complex with the insulin. This insulin formulation generally has a pH from between about 6.0 to about 7.4. In addition, the insulin formulation of the present invention does not contain other proteins like protamine. This zinc-modified formulation displays characteristics of a very long lasting human insulin product.

REFERENCES:
patent: 2626228 (1948-05-01), Petersen
patent: 2799622 (1957-07-01), Schlichtkrull et al.
patent: 2819999 (1958-01-01), Schlichtkrull et al.
patent: 2849370 (1958-08-01), Petersen et al.
patent: 2882202 (1959-04-01), Petersen et al.
patent: 2882203 (1959-04-01), Petersen et al.
patent: 3060093 (1962-10-01), Poulsen et al.
patent: 3102077 (1963-08-01), Christensen et al.
patent: 4476118 (1984-10-01), Brange et al.
patent: 5070186 (1993-12-01), Joergensen
patent: 5177058 (1993-01-01), Dorschug
Kirk-Othmer, Encyclopedia of Chemical Technology, 3rd Ed., vol. 13, John Wiley and Sons, NY 1981, pp. 607-614.
Diamant et al., Subcutaneous absorption of insulin in insulin dependent diabetic patients, Dan. Med. Bull., 38:4, 337-346 (1991).
Skyler, Insulin Treatment, Therapy for Diabetes Mellitus and Related Disorders, American Diabetes Assoc., Alexandria, VA, 127-137 (1991).
Tattersall, Bovine Insulin, BMJ, 305, 831 (1992).
Seigler et al., Pharmacokinetics of long-acting (ultralente) insulin preparations, Diabetes Nutrition & Metabolism, 4, 267-273.
Graham et al., An in-vitro test for the duration of action in insulin suspensions, J. Pharm. Pharmacol. 36, 427-430 (1984).
Francis et al., Human Ultralete Insulin, Diabetes Research, 3, 263-268 (1986).
Freeman et al., Use of human ultralente as the basal insulin component in treatment of patients with IDDM, Diabetes. Res. and Clin. Practice, 12, 187-192 (1991).
Fontbonne, Insulin-A Sex Hormone for Cardiolvascular Risk, Circulation, 84, 1442-1444 (1991).
Owens et al., Human, Procine and Bovine Ultralente Insulin:Subcutaneous Administration in Normal Man, Diabetic Medicine, 3, 326-329 (1986).
Holman et al., Human Ultralente Insulin, British Med. J., 288, 665-668 (1984).
Atkinson et al., Genetic Control of the Immune Response to Insulin, Insulin Action, 2, 183-192 (1989).
Hirsch et al., Intensive Insulin Therapy:Part I. Basic Principles, Amer. Family Physician, 45:5, 2141-2147 (1992).
Keen et al., Human Insulin Produced by Recombinant DNA Technology:Safety and Hypoglycaemic Potency in Healthy Men, The Lancet, 398-401 (1980).
Makita et al., Advanced Glycosylation End Products in Patents with Diabetic Nephropathy, The New England J. of Med., 836-842 (1991).
Arslanian et al., Etiology of the Dawn Phenomenon, Diab. Care, 15:7, 928-929 (1992).
Jorgensen et al., NovoSol Basal:Pharmacokinetics of a Novel Soluble Long Acting Insulin Analogue, BMJ, 299, 415-419 (1989).
Hansen, The self-association of zinc-free human insulin and insulin analogue B13-glutamine, Biophysical Chemistry, 39, 107-110 (1991).
Brange et al., Monomeric Insulins and Their Experimental and Clinical Implicaitons, Diab. Care, 13:9, 923-954 (1990).
Home et al., Bioavailability of Highly Purified Bovine Ultralente Insulin, Diab. Care, 6:2, 210 (1983).
Owens, Long-acting Insulin Preparations, Human Insulin Clinical Pharmacological Studies in Normal Man, 170-177 (1986).
Reeves et al., Insulin Antibodies Induced by Bovine Insulin Therapy, Clin. Exp. Immunol., 50, 163-170 (1982).
Walford et al., The Effect of Insulin Antibodies on Insulin Dose and Diabetic Control, Diabetologia, 22, 106-110 (1982).
Schlichtkrull, Chemical and Biological Studies on Insulin Crystals and Insulin Zinc Suspensions, Insulin Crystals (1958).
Hallas-Moller et al., Cystalline and Amorphous Insulin-Zinc Compounds with Prolonged Action, Science, 116, 394-398 (1952).
Brange et al., Galenics of Insulin; The Physico-chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations (1987).
Brange et al., Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations, Pharma. Res. 9:6, 715-726 (1992).

Affiliated with

Also associated with

Rating

Insulin formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Insulin formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1867255